Ireland
--:--IST
Latest
PulseAI of Belfast Says FDA Cleared Its Wearable ECG AI Airmid Éireann 1.6 Adds India and China Trials, Swiss Prices Irish Cancer Trial Enrolment at 2.9%, Under Half 6% Target FDA Accelerated Approval for J&J's Head and Neck Cancer Drug Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda ArrayPatch Closes €3.2m Seed for GLP-1 Microneedle Patch PulseAI of Belfast Says FDA Cleared Its Wearable ECG AI Airmid Éireann 1.6 Adds India and China Trials, Swiss Prices Irish Cancer Trial Enrolment at 2.9%, Under Half 6% Target FDA Accelerated Approval for J&J's Head and Neck Cancer Drug Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda ArrayPatch Closes €3.2m Seed for GLP-1 Microneedle Patch
Clinical Trials in China / NCT05582161
Recruiting Phase 2

Efficacy Biomarkers of DAOIB for Dementia

NCT05582161 · tracked via the Priya Life Science China tracker
Sponsor
Chang Gung Memorial Hospital
Phase
Phase 2
Started
2022-10-03
Last updated
2026-03-19

Condition(s) studied

Dementia

Investigational drug(s) / intervention(s)

DAOIB →

DAOIB: The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.

Study summary

This open-label clinical trial will enroll patients with aMCI or mild AD, and they will be treated with DAOIB for 24 weeks. We will assess the patients before entering the study, 8 weeks, 16 weeks, and end point (24 weeks) of the study, and measure blood NMDA and oxidative stress - related biomarkers every 8 weeks. We hypothesize that NMDA and oxidative stress - related biomarkers can predict the efficacy of DAOIB for patients with aMCI or mild AD.

Eligibility

Sex
ALL
Min age
50 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Clinical diagnosis of Alzheimer's disease or mild cognitive impairment * MMSE between 10-26 * CDR 1 or 0.5 Exclusion Criteria: * Hachinski Ischemic Score \> 4 * Substance abuse/dependence * Parkinson disease, epilepsy, dementia with psychotic features * Major depressive disorder * Major physical illnesses * Severe visual or hearing impairment

Primary outcome measure(s)

  • Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24 — week 0, 8, 16, 24
    Alzheimer's disease assessment scale-cognitive subscale scores range from 0 (best) to 70 (worst)

Trial sites (2)

FacilityCityRegionStatus
Chang Gung Memorial Hospital Kaohsiung City Taiwan Recruiting
China Medical University Hospital Taichung Taiwan Recruiting

More Chang Gung Memorial Hospital trials in China

Pacing Characteristics of a Conventional Bipolar Active, not recruiting

Other trials for the same condition

Fuzhou Aging Brain Health Initiative Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Active, not recruiting
Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study Recruiting
The Association Between Primary Aldosteronism and Cognitive Dysfunction Recruiting
Management of Age-Related Auditory Decline and Early Warning of Its Co-occurring Dementia Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05582161 on ClinicalTrials.gov ↗ ← All trials in China